1,944
Views
10
CrossRef citations to date
0
Altmetric
COVID-19 and Asthma

Clinical characteristics of COVID-19 patients with asthma in Wuhan, China: a retrospective cohort study

, MMed, , MPH, , MPH, , MMed, , MPH, , MPH, , MMed, , MMed, , MMed, , MMed & , MMed show all
Pages 230-238 | Received 23 Jun 2020, Accepted 08 Nov 2020, Published online: 30 Nov 2020
 

Abstract

Objective

Although it is reported that patients with coronavirus disease 2019 (COVID-19) disease who have comorbidities are at higher risk to suffer adverse clinical outcomes, there are inadequate evidence to clarify the association between COVID-19 and asthma. On this ground, this study aims to systematically analyze the clinical characteristics of COVID-19 patients with asthma.

Methods

In this single-center, retrospective and observational cohort study, 21 COVID-19 patients with asthma and 100 non-asthma COVID-19 patients were statistically matched by propensity score based on age, sex and comorbidities. Meanwhile, a collection and comparison concerning demographic indicators, clinical and laboratory examinations, treatments and outcomes were conducted between two groups to specify their differences.

Results

Statistically, the COVID-19 patients with asthma had a higher proportion of ICU admission (14.3% [3/21] vs. 2.1% [2/96] p = 0.040) than those who do not have. On top this, a higher level of inflammatory responses, such as interleukin 6, interleukin 8, procalcitonin, leukocytes, neutrophils and CD4+ T cells was presented in asthma patients. Moreover, the increase of organ damage indices like D-dimer, lactate dehydrogenase and high-sensitivity cardiac troponin I, were more pronounced in COVID-19 patients with asthma.

Conclusions

Exacerbated inflammatory responses and multiple organ damages were triggered in COVID-19 patients with asthma, which highlights more intensive surveillance and supportive treatment.

Acknowledgements

We acknowledge all patients and their families involved in the study and all health-care workers who are fighting against COVID-19 pneumonia.

Data availability statement

The data used to support the findings of this study are available from the corresponding author upon request (Huilan Zhang, Email: [email protected]).

Declaration of interests

The authors declare no conflicts of interest.

Additional information

Funding

This work was supported by SARS-CoV-2 Pneumonia Emergency Technology Public Relations Project of Tongji Medical College, Huazhong University of Science and Technology under Grant 2020kfyXGYJ043 and National Key Research and Development Program of China under Grant 2016YFC1304403.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,078.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.